This company listing is no longer active
Laboratorio Reig Jofre Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Laboratorio Reig Jofre's earnings have been declining at an average annual rate of -7.8%, while the Pharmaceuticals industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 9.1% per year. Laboratorio Reig Jofre's return on equity is 2.7%, and it has net margins of 2.1%.
Belangrijke informatie
-7.8%
Groei van de winst
-14.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 5.0% |
| Inkomstengroei | 9.1% |
| Rendement op eigen vermogen | 2.7% |
| Nettomarge | 2.1% |
| Volgende winstupdate | 26 Jul 2022 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Geen updates
Opbrengsten en kosten
Hoe Laboratorio Reig Jofre geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 21 | 240 | 5 | 74 | 0 |
| 30 Sep 21 | 237 | 6 | 77 | 0 |
| 30 Jun 21 | 234 | 6 | 76 | 0 |
| 31 Mar 21 | 234 | 6 | 76 | 0 |
| 31 Dec 20 | 234 | 6 | 76 | 0 |
| 30 Sep 20 | 229 | 8 | 75 | 0 |
| 30 Jun 20 | 229 | 6 | 72 | 0 |
| 31 Mar 20 | 219 | 6 | 70 | 0 |
| 31 Dec 19 | 206 | 5 | 68 | 0 |
| 30 Sep 19 | 199 | 7 | 68 | 0 |
| 30 Jun 19 | 188 | 9 | 67 | 0 |
| 31 Mar 19 | 188 | 9 | 66 | 0 |
| 31 Dec 18 | 185 | 9 | 65 | 0 |
| 30 Sep 18 | 185 | 10 | 60 | 0 |
| 30 Jun 18 | 179 | 9 | 59 | 0 |
| 31 Mar 18 | 175 | 9 | 58 | 0 |
| 31 Dec 17 | 172 | 9 | 58 | 0 |
| 30 Sep 17 | 164 | 5 | 58 | 0 |
| 30 Jun 17 | 164 | 7 | 57 | 0 |
| 31 Mar 17 | 164 | 8 | 57 | 0 |
| 31 Dec 16 | 161 | 8 | 55 | 0 |
| 30 Sep 16 | 160 | 5 | 55 | 0 |
| 30 Jun 16 | 159 | 5 | 54 | 0 |
| 31 Mar 16 | 156 | 5 | 53 | 1 |
| 31 Dec 15 | 157 | 9 | 53 | 0 |
Kwaliteitswinsten: RJF.D has high quality earnings.
Groeiende winstmarge: RJF.D's current net profit margins (2.1%) are lower than last year (2.4%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: RJF.D's earnings have declined by 7.8% per year over the past 5 years.
Versnelling van de groei: RJF.D's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: RJF.D had negative earnings growth (-10.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.9%).
Rendement op eigen vermogen
Hoge ROE: RJF.D's Return on Equity (2.7%) is considered low.